Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer

ABSTRACT: The primary aim of this study is to test whether the combination of valproic acid with bevacizumab and oxaliplatin/fluoropyrimidine regimens (mFOLFOX6/mOXXEL) can prolong progression free survival (PFS) as compared with bevacizumab and oxaliplatin/fluoropyrimidine regimens alone as first-line treatment in patients with metastatic colorectal cancer with mutation of RAS.

DISEASE(S): Ras-mutated Metastatic Colorectal Cancer,Colorectal Neoplasms,Valproic Acid

PROVIDER: 2333227 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR